Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.